Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment

Gynecol Oncol. 2015 Dec;139(3):419-23. doi: 10.1016/j.ygyno.2015.10.015. Epub 2015 Oct 19.

Abstract

Objective: To evaluate possible prognostic factors regarding regression and relapse of complex atypical hyperplasia (CAH) and well-differentiated endometrioid adenocarcinoma (WDC) treated with conservative treatment.

Methods: The retrospective study reviewed clinicopathologic, treatment, regression and relapse data from patients diagnosed with CAH or WDC who were treated with conservative treatment at 4 institutions. Potential factor evaluation was performed. SPSS 16 was used for statistical analyses.

Results: Eighty-eight patients were included (51 had WDC, and 37 had CAH). Regression was evaluated in 88 patients, with a median follow-up of 61 (range 15-95) months. Seventy-seven (87.5%) patients regressed, and 11 (12.5%) had persistent or progressive disease. Univariate and multivariate analyses showed no factors associated with regression. Relapse was evaluated in 71 patients, with median follow-up of 54 (range 8-86) months. Twenty-five/71 (35.2%) patients experienced relapse. On univariate analysis, body mass index (BMI) 30 or higher (p=0.001), WCD at initial biopsy (p=0.017) and positive expression of post-treatment ki67 (p=0.033) were associated to a higher relapse probability. However, only BMI 30 or higher was significant on multivariate analysis (p=0.012). The Kaplan-Meier analysis revealed a higher relapse probability in the patients with BMI 30 or higher (p=0.001).

Conclusion: Obesity seems to be a risk factor for relapse of CAH or WDC with conservative treatment.

Keywords: Complex atypical hyperplasia; Conservative treatments; Endometrioid carcinoma; Regression; Relapse.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Body Mass Index
  • Carcinoma, Endometrioid / drug therapy
  • Carcinoma, Endometrioid / pathology*
  • Disease Progression
  • Endometrial Hyperplasia / drug therapy
  • Endometrial Hyperplasia / pathology*
  • Endometrial Neoplasms / drug therapy
  • Endometrial Neoplasms / pathology*
  • Female
  • Humans
  • Neoplasm Recurrence, Local / pathology*
  • Prognosis
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult

Substances

  • Antineoplastic Agents, Hormonal